Evidence map›Paper›PMID 32995801›Full record

ArticlemedRxiv : the preprint server for health sciences2020

SARS-CoV-2 antibody signatures robustly predict diverse antiviral functions relevant for convalescent plasma therapy.

Harini Natarajan, Andrew R Crowley, Savannah E Butler, Shiwei Xu, Joshua A Weiner, Evan M Bloch, Kirsten Littlefield, Wendy Wieland-Alter, Ruth I Connor, Peter F Wright and 12 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 33 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

  • Updated by
5 · Who and what money

Authors and funding

22 authors at 4 institutions in 1 country.

Harini NatarajanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Andrew R CrowleyDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Savannah E ButlerDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Shiwei XuThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Joshua A WeinerThayer School of Engineering, Dartmouth College, Hanover, NH, USA.
Evan M BlochDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Kirsten LittlefieldW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Wendy Wieland-AlterDepartment of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Ruth I ConnorDepartment of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Peter F WrightDepartment of Pediatrics, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Sarah E BennerDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Tania S BonnyDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Oliver LaeyendeckerDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
David SullivanW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Shmuel ShohamDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Thomas C QuinnDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
H Benjamin LarmanDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Arturo CasadevallW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Andrew PekoszW. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Andrew D ReddDepartment of Medicine, Division of Infectious Diseases, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Aaron A R TobianDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Margaret E AckermanDepartment of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Dartmouth College, Hanover, NH, USA.
Johns Hopkins University · USDartmouth College · USDartmouth–Hitchcock Medical Center · USNational Institutes of Health · US

Funding

Translational Engineering in Cancer (TEC)P30CA023108 · NCI · DARTMOUTH COLLEGE · PI Steven D Leach · 1985 to 2026
$91.3M
Understanding the role of RNA-binding protein mutations in cancerP20GM113132 · NIGMS · DARTMOUTH COLLEGE · PI MADDEN, DEAN R · 2016 to 2025
$25.9M
IMMUNOBIOLOGY OF MYELOID AND LYMPHOID CELLST32AI007363 · NIAID · DARTMOUTH COLLEGE · PI Claudia V Jakubzick · 1990 to 2026
$9.5M
Synergy of Host Defense Mechanisms in the LungR01HL059842 · NHLBI · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 1997 to 2023
$7.4M
Biology of Fungal MelaninR01AI052733 · NIAID · YESHIVA UNIVERSITY · PI CASADEVALL, ARTURO · 2003 to 2019
$6.6M
Johns Hopkins HIV Epidemiology and Prevention Sciences Training ProgramT32AI102623 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Shruti H Mehta · 2013 to 2026
$5.3M
Unlocking the Potential of HIV-Infected Deceased Donors for Organ TransplantationR01AI120938 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2016 to 2021
$4.3M
Penile Microbiome, Inflammation and HIV Susceptibility During Sexual Debut and Maturation Among Male AdolescentsR01AI128779 · NIAID · JOHNS HOPKINS UNIVERSITY · PI TOBIAN, AARON A · 2017 to 2020
$2.1M
The Malaria Transfusion Risk (MATRix) StudyK23HL151826 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI BLOCH, EVAN MARTIN · 2020 to 2024
$882k
A prospective evaluation of chronic B.microti infection in seroreactive blood donR21HL117140 · NHLBI · VITALANT · PI BLOCH, EVAN MARTIN · 2013 to 2014
$452k
NCI NIH HHS P30 CA023108NHLBI NIH HHS K23 HL151826NHLBI NIH HHS R01 HL059842NIAID NIH HHS HHSN272201400007CNIAID NIH HHS HHSN272201400008CNIAID NIH HHS R01 AI052733NIAID NIH HHS R01 AI120938NIAID NIH HHS R01 AI128779NIAID NIH HHS T32 AI007363NIAID NIH HHS T32 AI102623NIGMS NIH HHS P20 GM113132
6 · The paper itself

Abstract

Convalescent plasma has emerged as a promising COVID-19 treatment. However, the humoral factors that contribute to efficacy are poorly understood. This study functionally and phenotypically profiled plasma from eligible convalescent donors. In addition to viral neutralization, convalescent plasma contained antibodies capable of mediating such Fc-dependent functions as complement activation, phagocytosis and antibody-dependent cellular cytotoxicity against SARS-CoV-2. These activities expand the antiviral functions associated with convalescent plasma and together with neutralization efficacy, could be accurately and robustly from antibody phenotypes. These results suggest that high-throughput profiling could be used to screen donors and plasma may provide benefits beyond neutralization.

Indexed as

ADCCConvalescent plasmaCOVID-19functional antibody responseneutralizationphagocytosisSARS-CoV-2

Identifiers

PMID32995801
PMCPMC7523138
OpenAlexW3087482738

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.